[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336916-105":59,"doc-detail-336916-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeted-degradation-of-the-hpv-oncoprotein-e6-reduces-tumor-burden-in-cervical-cancer","Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer","","Human Papilloma Virus (HPV)-related cancers remain a major global health burden, with no targeted therapies for chronically infected patients. HPV protein E6 is essential for tumorigenesis and immune evasion, making it a compelling antiviral drug target. Here, an E6-targeting PROTAC was engineered to degrade E6 via the CRL2VHL pathway. Intralesional delivery with a clinically viable DNA vaccine reduced tumor burden in an immunocompetent mouse model, with antitumor effects dependent on CD4+ and CD8+ T cells. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-degradation-of-the-hpv-oncoprotein-e6-reduces-tumor-burden-in-cervical-cancer/336916/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-degradation-of-the-hpv-oncoprotein-e6-reduces-tumor-burden-in-cervical-cancer/336916.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is HPV E6 considered a promising therapeutic target?","Question",{"text":112,"@type":113},"HPV E6 is essential for tumor initiation, maintenance, and progression, and it helps the virus evade host immune responses by antagonizing innate immune signaling pathways.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What strategy was developed to target E6?",{"text":117,"@type":113},"The study engineered an E6-targeting PROTAC by fusing an E6 nanobody (A5) to Von Hippel Lindau (VHL) to induce E6 degradation via the CRL2VHL E3 ligase.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the PROTACE6 affect tumor burden in vivo, and what role did immunity play?",{"text":121,"@type":113},"Intralesional administration of PROTACE6 reduced tumor burden in an immunocompetent mouse model of HPV(+) cancer. Depletion of CD4+ and CD8+ T cells abrogated the inhibitory effect, showing dependence on host immune response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336916,1790210874,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","bioRxiv preprriinntt doi:i: https://doi://doi.org/10.1101/2024.10.17.618959; this version posted October 17 ,, 2024. The copyrightright holder for this preprint (whichiich was not certiiffiieedd by peer reviiew)ew) iisis the author/funder,, who has granted bioRxiv a license to display the preprint iin perpetuity. IItIt is made  \navailableiilable under aCC-BY-ND 4.0 Internationalional licensellicense.  \nTitle: Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer  \nAuthors: Tracess B Smalley 1 , Angelo Nicolaci 1,4 , Kim C. Tran5 , Jameela Lokhandwala 1 , Nina Obertopp2,4 , Jenet K Matlack 1,3 , Robert E Miner III 1,4 , Michael N. Teng5 , Shari Pilon-Thomas2 , and Jennifer M Binning 1  \n1 Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.  \n2 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.  \n3 Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, 33612, USA.  \n4 Cancer Biology PhD Program, University of South Florida, Tampa, Florida, 33612, USA.  \n5 Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, 33612, USA.  \n* Correspondence should be addressed to Jennifer M. Binning ([jennifer.binning@moffitt.org](jennifer.binning@moffitt.org))  \nAbstract:  \nHuman Papilloma Virus (HPV)-related cancers are a global health burden, yet there are no targeted therapies available for chronically infected patients. The HPV protein E6 is essential for HPV-mediated tumorigenesis and immune evasion, making it an attractive target for antiviral drug development. In this study, we developed an E6-targeting Proteolysis Targeting Chimera (PROTAC) that inhibits the growth of HPV(+) tumors. To develop E6 antagonists, we generated a panel of nanobodies targeting E6 proteins derived from the oncogenic HPV16 subtype. The highest affinity E6 nanobody, A5, was fused to Von Hippel Lindau protein (VHL) to generate a PROTAC that degrades E6 (PROTACE6 ) . Mutational rescue experiments validated specific degradation via the CRL2VHL E3 ligase. Intralesional administration of the PROTACE6 using a clinically viable DNA vaccine reduced tumor burden in an immunocompetent mouse model of HPV(+) cancer. The inhibitory effect of the PROTACE6 was abrogated by CD4+ and CD8+ T-cell depletion, indicating that the antitumor function of the PROTACE6 relies in part on a host immune response. Overall, these results suggest that the targeted degradation of E6 inhibits its oncogenic function and stimulates a robust immune response against HPV(+) tumors, opening new opportunities for virus-specific therapies in the treatment of HPV-related cancers.  \nbioRxiv preprint doi: [https://doi.org/10.1101/2024.10.17.618959](https://doi.org/10.1101/2024.10.17.618959); this version posted October 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nBackground:  \nMore than 80% of sexually active individuals will acquire human papillomavirus (HPV), making it the most prevalent sexually transmitted infection globally 1 . Persistent HPV infections cause up to six different cancers and are associated with nearly all cervical cancers and ~25% of head and necksquamous cell carcinomas (HNSCCs)2 . Despite the high efficacy of prophylactic HPV vaccines in preventing cervical cancer, HPV continues to contribute to 5% of the global cancer rates3. As there are currently no FDA-approved targeted therapies for the treatment of chronic HPV infections or HPVassociated malignancies, a large fraction of the global population remains at risk for HPV-related cancer4 .  \nHPV-positive (HPV+) cancers depend on the expression of the viral E6 oncoprotein for tumor ","cbCaimv1bqJI6X3W","https://ap.wps.com/l/cbCaimv1bqJI6X3W","pdf",1663642,"English","# Abstract\n# Background\n## Global impact of HPV\n## Role of E6 in tumor biology\n## Therapeutic strategies targeting E6","[{\"question\":\"Why is HPV E6 considered a promising therapeutic target?\",\"answer\":\"HPV E6 is essential for tumor initiation, maintenance, and progression, and it helps the virus evade host immune responses by antagonizing innate immune signaling pathways.\"},{\"question\":\"What strategy was developed to target E6?\",\"answer\":\"The study engineered an E6-targeting PROTAC by fusing an E6 nanobody (A5) to Von Hippel Lindau (VHL) to induce E6 degradation via the CRL2VHL E3 ligase.\"},{\"question\":\"How did the PROTACE6 affect tumor burden in vivo, and what role did immunity play?\",\"answer\":\"Intralesional administration of PROTACE6 reduced tumor burden in an immunocompetent mouse model of HPV(+) cancer. Depletion of CD4+ and CD8+ T cells abrogated the inhibitory effect, showing dependence on host immune response.\"}]","Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer | PDF",1790017052,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23d389cbf94521bc4f2c47b1d53b9df1.webp",983,1272,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d59db332c8ae2e3bb61d5cd4d50bb1e7.webp",982,1270,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08581c721557e9b3a754150898ae32f4.webp",981,1269,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce8e9d537a383b5186937323b80dbf00.webp",980,1268]